Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
skin infections
Biotech
Recce's synthetic gel treats skin infections in ph. 2
Recce’s synthetic anti-infective treated a range of skin infections in a mid-stage trial, setting the Australian biotech’s sights on a phase 3 trial.
James Waldron
Feb 19, 2025 8:39am
Histogen halts last remaining programs to conserve cash
Jul 6, 2023 9:00am
Nabriva halts R&D, lays off 40% of staff in commercial refocus
Nov 11, 2022 7:35am
After cancer flops, Celldex shows promise in treating hives
Jul 12, 2021 8:05am
AnaptysBio's dermatology drug misses the mark in phase 2
Mar 8, 2021 9:35am
Lilly bags late-phase Dupixent rival in $1.1B Dermira buyout
Jan 10, 2020 8:20am
